ArticleOncotarget2017
Gamma analysis with a gamma criterion of 2%/1 mm for stereotactic ablative radiotherapy delivered with volumetric modulated arc therapy technique: a single institution experience.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Impact of Optimization Resolution and Dose Calculation Grid Size in Small-Field Stereotactic Body Radiotherapy Using Flattening-Filter-Free Beams for Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Clinical evaluation of the aperture shape controller in volumetric modulated arc therapy: Effects on MLC and jaw motion complexity, plan quality, and deliverability.Journal of applied clinical medical physics · 2025Article
- Classification performances of two diode arrays for patient-specific quality assurance of stereotactic body radiation therapy treatments based on absolute dose measurements in phantom.Journal of applied clinical medical physics · 2025Article
- Systematic evaluation of spatial resolution and gamma criteria for quality assurance with detector arrays in stereotactic radiosurgery.Journal of applied clinical medical physics · 2024Article
- Improvement of deep learning prediction model in patient-specific QA for VMAT with MLC leaf position map and patient's dose distribution.Journal of applied clinical medical physics · 2023Article
- Dosimetric Validation of a GAN-Based Pseudo-CT Generation for MRI-Only Stereotactic Brain Radiotherapy.Cancers · 2021Article
- Development and validation of a comprehensive patient-specific quality assurance program for a novel stereotactic radiation delivery system for breast lesions.Journal of applied clinical medical physics · 2019Article
- Comparing phase- and amplitude-gated volumetric modulated arc therapy for stereotactic body radiation therapy using 3D printed lung phantom.Journal of applied clinical medical physics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To report a single-institution experience of gamma evaluations with 2%/1 mm for stereotactic ablative radiotherapy (SABR) delivered with volumetric modulated arc therapy (VMAT) technique, from January 2014 to January 2016. A total of 168 SABR VMAT plans were analyzed with a gamma criterion of 2%/1 mm, a threshold value of 10%, and a tolerance level of 90%. Of the 168 cases, four cases failed with 2%/1 mm. The average passing rate was 97.0% ± 2.5%. Three of the four failed cases showed passing rates higher than 90%, which was achieved by shifting the measuring device by 1 mm in the left-to-right or anterior-to-posterior directions. One failed case showed a passing rate higher than 90%, which was achieved by changing the threshold value from 10% to 5%, leading to an increase in the number of tested points from 26 to 51. Concerns regarding the high susceptibility of the gamma criterion of 2%/1 mm to setup errors of the measuring device are unnecessary based on our two-year experience, since only four cases failed with the 2%/1 mm from a total of 168 clinical cases. Therefore, the gamma criterion of 2%/1 mm could be successfully applied in the clinic with its high sensitivity to detect errors in VMAT plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.